Abstract -Neuromyelitis optica (NMO) is an inflammatory, demyelinating disease of the central nervous system characterized by the association of a serious myelitis and unilateral or bilateral optic neuritis. The present study aimed to analyze the immunological parameters of NMO patients with diagnosis established based on Wingerchuck et al. (1999) criteria. Production of IgG and IgA antibodies to antigens of MBP, PLP 95-116, MOG 92-106, and the cytokines interleukin-4 (IL-4) and interferon-γ (INF-γ) were assessed by Elisa assay. The cohort was formed by 28 NMO patients and a matched healthy control group. NMO patients had significant high levels of IgG to MOG (p<0.0001), PLP (p=0.0002) and MBP (p<0.0001), and solely IgA to MBP (p<0.0001). INF-γ (p=0.61) levels were similar to healthy controls. Increased production of IL-4 (p=0.0084) indicates an important role for this cytokine in the activation of Th2 regulatory cells and of the IgA producers B lymphocyte indicating activation of humoral immunity.
Neuromyelitis optica (NMO) was described, for the first time, in 1894, by Eugène devic 1 and further considered a variant of multiple sclerosis (Ms) or a distinct syndrome 2, 3 . Acute transverse myelitis can be the first symptom. One or more episodes of optic neuritis (ON) can occur in combination with myelitis, been more acute and severe in this case. The interval between ON and myelitis is variable; when monophasic the interval is shorter. Optic neuritis can be unilateral or bilateral. The paraclinical diagnose is made with brain MrI, spinal cord MrI and cerebrospinal fluid (CsF) analysis. The brain MrI can be normal at the onset of NMO or show non-specific white-matter Neuromyelitis optica: neuroinflammation Alves-Leon et al.
lesions that do not satisfy neurological criteria for Ms [3] [4] [5] .
MrI of the spinal cord shows longitudinally extensive lesions and characteristically span three or more contiguous vertebral segments [4] [5] [6] [7] [8] . Prominent CsF pleocytosis with more than 50 leucocytes with neutrophil predominance is characteristic of NMO and rare in Ms. The synthesis of IgG is smaller than seen in Ms. Therefore the oligoclonal bands which mean intrathecal synthesis of immunoglobulin are found only in 23% of NMO patients, but in 88% of Ms patients 4 . The supportive diagnose is based on the presence of autoantibodies which are found in 50% of the cases, on the visual evoked potential (subclinical ON) and on brain MrI with gadolinium enhancement of the optic nerves or chiasm. since its description NMO was considered a variant of Ms. The pathologic studies, the CsF and the MrI showed evidences that it should be a distinctive disease. The diagnostic criteria had been established only in 1999, by Wingerchuck et al. 9 and were divided into absolute criteria, major supportive criteria and minor criteria. recently, Lennon et al. 10, 11 reported a serum autoantibody to immunoglobulin G, which is a specific marker to NMO, NMO-IgG, to be selectively linked to the acquaporin-4 channels (AQP-4), a component of the protein distroglican complex, localized in the endfeet of astrocytes, processed in the blood-brain barrier 10, 11 . The high prevalence of autoantibodies in NMO and its association to collagen diseases suggest a malfunction of B cells immunity 12 and the detection of the autoantibody NMO-IgG corroborate this observation 13 . Lucchinetti et al.
14 revealed demyelinated lesions in association to perivascular deposits of immunoglobulin, local activation of the complement cascade and eosinophil infiltration, suggesting a humoral immunity in its pathogenesis 14, 15 . Another mechanisms involved in this humoral reaction would be the production of the antibody antimyelin oligodendrocyte glycoprotein (anti-MOG) and secretion of interleukin-2 (IL-2), a cytokine related to autoimmunity due to T cells. NMO is the first CsN idiopathic, demyelinated disease to have a specific biological marker and can represent the first example of a new class of an autoimmune channelopathy 10 . Through the AQP-4 channels, small, but important quantities of peripheral immunoglobulin can reach the CNs at the vulnerable regions of the blood-brain barrier 10, 12, 16 . The goal of this study was to determine the serum levels of IgG and IgA antibodies to antigens of myelin basic protein (MBP), proteolipid (PLP) 95-116, myelin oligodendrocyte glycoprotein (MOG) 92-106, and the cytokines interleukin-4 (IL-4) and interferon-γ (INF-γ) in NMO patients comparing to healthy controls. results Among 28 NMO patients, 21 were females (75%) and seven males. Taking into account the ethnic group, 14 patients (50%) were Afro-descendents and 14 were Caucasians (50%). The control group was composed of 28 healthy individuals, 15 (58%) were females and 11 (42%) males; 21 (81%) were Caucasians and five (19%) were AfroBrazilians. Ages ranged from 18 to 43 years old. (7) 58% (15) 42% (11) Ethnic group Caucasians Afro-Brazilians 50% (14) 50% (14) 81% (21) 19% (5) Age (years) At the moment of inclusion At the onset of symptoms 24 to 62 8 to 46 Table 1 describes patients characteristics related to sex, ethnic group, age of inclusion in the study, disease duration, age of the first bout, interval between the first and second bouts, total number of bouts and actual Edss.
The age of symptom onset varied from eight to 46 years old (mean age=27 years), 21.4% younger than 20 years old, 32.1% between 20 and 30 years old and 46.5% older than 30 years old. Considering the first bout, optical neuritis was the most common symptom, found in 13 patients (46.4%). Two of them had bilateral optical neuritis (15.4% of all the optical neuritis in the study). Eight patients (28.6%) had transverse myelitis. Optical neuritis and myelitis were present as a first bout in seven patients (25%). The recurrent presentation of NMO was prevalent in our series (92.8%). The interval between the index events varied from three to 228 months and in seven cases they were simultaneously. The mean duration of the disease was 17.5 years, ranging from six to 29 years (Table 2). Three patients (10.7%) patients had it for five years and 25 (89.3%) had it for more than five years. In our series there were no deaths. The average number of bouts in the recurrent forms was 8.5 (2 to 15); seven patients (25%) had more than one bout per year, all Afro-Brazilians. during the bouts all patients were treated with endovenous methylprednisolone, 1 g/day/3 days, repeated during 3 to 5 weeks. Nine patients (32.14%) had an Edss ≥4 when entering the study group; 66.66% were Afro-descendents and 33.4% were Caucasians. Tables 3 and 4 synthesized our results.
Laboratorial results
The results and statistical significance found in NMO patients and control groups are found in Table 5 . The Mann-Whitney test was applied. The plasma of each patient and control were analyzed three times.
We found higher levels of IgG and IgA antibodies to native MBP with statistic significance (p<0.0001) in NMO patients compared to the controls. Od, optic density.
The blood levels of IgG to PLP 95-116 were also higher with statistic significance (p=0.0002) in NMO patients compared to controls, although this was not observed in PLP 95-116 IgA (p=0.0423).
NMO patients had an expressive (p<0.001) higher blood levels of IgG antibodies to MOG 92-106 but the IgA antibodies to the same sequence did not show statistic significance (p=0.2168).
The plasmatic levels of IFN-γ did not show statistic significance in the group of NMO patients (p=0.6109) although the IL-4 plasmatic levels were significantly higher (p=0.0084) in this group compared to the control group.
dIscussIon
In the last years the classification of NMO, a disease considered to be a Ms variant until recently, had changed. The description of the first biological marker highly sensitive and specific to NMO 10, 14 , clearly directed the classification of NMO to a distinct nosological condition 4, 10, 12, 19, 20 In our Neurological services there were 16.8% NMO patients, which is higher than Pirko et al. 21 found (12.5%).
They only considered patients with ON who turned to be NMO during five years of follow-up and not the totality of patients with demielinization of the central nervous system (CNs). They also found a higher number of women in their study group.
Among our 28 NMO patients there were 75% of women (3:1), similar to what we found in the literature by Bergamaschi and Ghezzi 22 , Papais-Alvarenga et al. 23 ; Cree et al.
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; O'riordan et al. 3 . We found 50% of Afro-descendents, not so different (58%) from the findings of Papais-Alvarenga et al. 23 . Another authors, Wingerchuk et al.
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, Bergamaschi and Gezzi 22 , Cree 5 , Wingercuk et al. 6 and O'riordan et al. 3 also found similar clinical and demographic characteristics, with a predominance of women and non-Caucasians among their NMO patients. The high number of Afro-descendents in our group should be related to the racial miscegenation in Brazil, especially in the southeast regions (Alves-Leon et al.) 24 .
Poser and Vernant 25 analyzed the association among NMO and endocrinopathies in Martinique, and suggested this to be a distinct nosological condition. The actual knowledge of the distribution of acquaporin channels in the CNs and their relation to NMO diagnosis lead us to conclude that NMO patients can have endocrinopathies due to the diencephalon compromise, what may have been seen in the Martinique Afro-descendents patients 24, 25 . Our NMO patients did not have endocrinopathies.
The index event in our patients with NMOr occurred in ages older than 30 years (46.5%), similar to the literature 4, 9, 22, 26, 27 . Among the initial symptoms there were: unilateral optical neuritis (39.3%) or bilateral (7.1%), myelitis (28.6%) and neuritis plus myelitis (25.0%). Another authors also observed unilateral optical neuritis as the main manifestation in their patients 9, 22 . The interval of time between the first and the second event, neuritis or myelitis, in NMOr, was among three and 228 months which are not in concordance to the literature. Wingerchuck et al. 19 analyzing 96 NMO patients, 84.4% (81 patients) with recurrent presentation, found this interval to be four to 48 months. Another authors observed similar interval 4, 5, 14, 22 , although Wingerchuk et al. 9 considered even years and Ghezzi et al. 28 considered one to 120 months, which is still a smaller interval than ours.
In our study the majority of patients (89.3%) had 17.5 years as a median duration of disease and there were no deaths. These results showed a higher longevity than we found in the literature where the mortality rate was 30% in five years 4, 9, 29 . The high morbidity observed by scolding 30 in another study where 50% of the patients had unilateral or bilateral amaurosis, walked with aid after five years were not seen in our patients. In our group, only five (17.8%) had a final Edss≥6.0.
The final Edss was not related to the gap of time between the first and second bouts, as described by Ghezzi et al. 28 who observed an important incapacity (Edss≥6.0)
in those patients with a longer gap among the bouts 22,24 .
These authors characterized the variables related to worst prognosis (Edss≥6): residual Edss ≥3 at the beginning of the disease, longer interval between the first and second bouts and a high number of relapses during the first two years of disease. In our casuistic we did not find relation among the Edss, total number of bouts nor the time between the first and second bouts that could suggest distinct evolutional characteristics from other populations.
We found high levels of all autoantibodies analyzed in this study. MOG 92-106, PLP 95-116 and MBP levels were higher in NMO patients with statistic significance which can be related to polyclonal activation of the humoral system as it was suggested by Hasse and schmidt 31 . The participation of MBP in the EAE model is well studied but recent EAE models investigate the participation of another autoantibodies, like MOG and PLP. The search for prognostic markers in Ms evolution in the work of Berger et al. 23 showed that patients with clinical isolated syndrome (CIs) like optic neuritis, myelitis, medulla or cerebellar syndrome with a positive MOG and MBP autoantibodies had a higher risk of conversion to a second bout, defining the disease in at least 12 months. This study did not mentioned the type of evolution but point out for the possibility of an initial investigation in patients with isolated optic neuritis and/or myelitis with positive MOG or MBP antibodies, observing their participation in the conversion to NMO. These studies would have an strategic implication in therapeutics.
The participation of encephalithogenic autoantibodies in the CNs IIddA was thought from an EAE animal model for Ms. Another models noticed that EAE could be induced through the immunization of susceptible animals with myelin antigens like MOG, MBP e PLP 33 . Betelli et al. 33 described an EAE model where B and T cells were specific to the same MOG autoantigen, developing spontaneous and severe EAE with inflammatory lesions mainly in the optic nerves and vertebral column of affected mice, a typical pattern of human NMO. The different EAE models and the immuno-pathologic studies of Ms suggested that the immune-mediated response by T cells should be crucial in the deflagration of the inflammatory process and that the auto-reactivity reaction of these cells should be insufficient to explain the selective destruction of myelin 34 . Lucchinetti et al. 14 emphasized the importance of humoral immune mechanisms in EAE showing that the extensive demyelinization is without T cells specificity. Therefore, indicate that T cells response against any CNs protein is potentially pathogenic, considering that it is followed by an adequate B cells response 35 . In our study we investigated the presence of antibodies to MOG, MBP and PLP in relation to the high levels of IL-4 and IFN-γ, molecules Th1/Th2 mediated.
We found expressive high levels of IL-4 (p=0.0084) in our patients different from the IFN-γ levels. The IFN-γ effects are partially blocked by IL-4 in the infectious diseases, a cytokine product by Th2 cells which stimulate B cells and the auto-immunity of the specific myelin B cells 36, 37 . Indeed, the high production of IgA to the myelin basic protein suggests higher participation of Th2 regulatory cells and B lymphocytes than Th1, in our patients. We have to consider the Afro-descendents in our study group who have a known Th2 pattern of immunity (regulatory), maybe inducted by MBP. In this context it would be interesting to sequentially analyze, in patients with different ethnics, a possible change in the profile of the neuro-inflammatory response during NMO clinical evolution, which means the change of the isotype IgM to IgG and/or IgA, configuring a more inflammatory (IgM, IgG; complement activation, IFN-γ) or regulatory (IgG, IgA, IL-4, TGF beta) response.
Our results can contribute to the search and determination of biologic markers related to NMO and its evolution. A Th2 humoral response mediated by B lymphocites was more prominent than Th1. Considering this profile of auto-reactivity, the levels of IFN-γ and IL-4 could represent the instrument of measure of the therapeutic response to the monoclonal antibodies, like rituximab, during the treatment of NMO patients. Also, the high expression of MOG 92-106, PLP 95-116 and MBP autoantibodies in NMO patients could be a marker of prognosis, recurrence or severity of the disease in patients treated with plasmapheresis.
As a limitation of our study we point out the relative small number of patients which did not allowed us to correlate demographic and clinical parameters of morbidity in NMO with the plasmatic levels of IL-4, IFN-γ.
references

